EDAP TMS SA (EDAP) is a publicly traded Healthcare sector company. As of May 21, 2026, EDAP trades at $4.25 with a market cap of $165.67M and a P/E ratio of -5.29. EDAP moved -0.46% today. Year to date, EDAP is +19.72%; over the trailing twelve months it is +123.68%. Its 52-week range spans $1.21 to $5.05. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces EDAP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
EDAP and Telix Sign Letter of Intent to Integrate Robotic HIFU with PSMA PET: EDAP TMS signed a letter of intent with Telix Pharmaceuticals to jointly research integration of Focal One Robotic HIFU with PSMA PET imaging for primary and salvage prostate cancer treatments. Based on positive HIFI-2 outcomes, the collaboration aims to improve patient outcomes by integrating PSMA PET scans within the HIFU treatment workflow.
| Metric | Value |
|---|---|
| Price | $4.25 |
| Market Cap | $165.67M |
| P/E Ratio | -5.29 |
| EPS | $-0.82 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.05 |
| 52-Week Low | $1.21 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $74.07M |
| Net Income | $-30.89M |
| Gross Margin | 43.41% |
1 analysts cover EDAP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.